Oceania & ASSEAN - Articles and news items


Aeterna Zentaris’ Zoptrex granted licensing agreement for Australia and New Zealand

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

Zoptrex, a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer…

Santhera’s Duchenne muscular dystrophy treatment receives Australian orphan drug designation

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

The Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation to Santhera Pharmaceutical’s idebenone (raxone) for the treatment of Duchenne muscular dystrophy (DMD). The product has already received ODD from European, Swiss and US authorities…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...